SCHEMBL12246778

SCHEMBL12246778

Cc1ccc(CCOC(=O)/C=C/c2ccc(O)c(O)c2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 8/20 0.81
TTR P02766 4/20 0.77
CYP3A4 P08684 2/20 0.77
ALOX15 P16050 2/20 0.77
ALOX12 P18054 2/20 0.77
MAPK1 P28482 2/20 0.77
HSD17B10 Q99714 2/20 0.77
KDM4E B2RXH2 1/20 0.77
MEN1 O00255 1/20 0.77
AKR1B10 O60218 1/20 0.77
GMNN O75496 1/20 0.77
ALDH1A1 P00352 1/20 0.77
EGFR P00533 1/20 0.77
LMNA P02545 1/20 0.77
ESR1 P03372 1/20 0.77
ERBB2 P04626 1/20 0.77
LCK P06239 1/20 0.77
FYN P06241 1/20 0.77
ALOX5 P09917 1/20 0.77
MAPT P10636 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29689052 1.00 APP (0.81) APPTTRCYP3A4ALOX15ALOX12
SCHEMBL12246699 0.91 APP (0.67) APPTTRCYP3A4ALOX15ALOX12
Tyrosol Caffeate SCHEMBL30977097 0.90 CA12 (0.86) APPTTRCYP3A4ALOX15ALOX12
Tyrosol Caffeate SCHEMBL12246677 0.90 CA12 (0.86) APPTTRCYP3A4ALOX15ALOX12
SCHEMBL12246693 0.89 APP (1.00) APPTTRCYP3A4ALOX15ALOX12
SCHEMBL27771959 0.89 APP (1.00) APPTTRCYP3A4ALOX15ALOX12
SCHEMBL12246671 0.88 APP (0.62) APPTTRCYP3A4ALOX15ALOX12
SCHEMBL14432078 0.88 MET (0.85) APPTTRCA12CA4CA6
SCHEMBL12246692 0.88 APP (0.85) APPTTRCYP3A4ALOX15ALOX12
SCHEMBL20914985 0.88 APP (0.77) APPTTRCYP3A4ALOX15ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423429-B1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-07-12 EP claimed
US-20230391711-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-12-07 US disclosed
EP-4276089-A2 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY Universite De Moncton (CA) 2023-11-15 EP disclosed
EP-4276089-A2 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY Universite De Moncton (CA) 2023-11-15 EP disclosed
US-11760715-B2 Modulators of lipoxygenase and cyclooxygenase enzyme activity UNIVERSITÉ DE MONCTON (CA) 2023-09-19 US disclosed
US-11760715-B2 Modulators of lipoxygenase and cyclooxygenase enzyme activity UNIVERSITÉ DE MONCTON (CA) 2023-09-19 US disclosed
US-11760715-B2 Modulators of lipoxygenase and cyclooxygenase enzyme activity UNIVERSITÉ DE MONCTON (CA) 2023-09-19 US disclosed
EP-3423429-B1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-07-12 EP disclosed
EP-3423429-B1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-07-12 EP disclosed
US-20220211653-A1 COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH THE UNIVERSITY OF NEW BRUNSWICK (CA) 2022-07-07 US disclosed
WO-2020210920-A1 COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH UNIVERSITY OF NEW BRUNSWICK (CA) 2020-10-22 WO disclosed
US-20190119194-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIVERSITE DE MONCTON (CA) 2019-04-25 US disclosed
US-20190119194-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIVERSITE DE MONCTON (CA) 2019-04-25 US disclosed
US-20110237551-A1 Para-Coumaric Acid or Para-Hydroxycinnamic Acid Derivatives and Their Use in Cosmetic or Dermatological Compositions BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) 2011-09-29 US disclosed
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds GILEAD SCIENCES, INC. 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220211653-A1 COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH MCL1, BCL9, HCLS1 APP 4643/4885TTR 1072/4885CYP3A4 4148/4885
US-20110237551-A1 Para-Coumaric Acid or Para-Hydroxycinnamic Acid Derivatives and Their Use in Cosmetic or Dermatological Compositions TYR, CUTA, HPD APP 2129/4885TTR 4460/4885CYP3A4 699/4885
US-11760715-B2 Modulators of lipoxygenase and cyclooxygenase enzyme activity ALOX12, ALOX15B, ALOX5 APP 3143/4885TTR 3270/4885CYP3A4 410/4885
US-20190119194-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ALOX12, ALOX15B, ALOX5 APP 3143/4885TTR 3270/4885CYP3A4 410/4885
US-20230391711-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ALOX12, ALOX15B, ALOX5 APP 3143/4885TTR 3270/4885CYP3A4 410/4885
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds TYMP, PNP, PIKFYVE APP 2820/4885TTR 4464/4885CYP3A4 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.